Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
GADD45A is a mediator of mitochondrial loss, atrophy, and weakness in skeletal muscle
George R. Marcotte, … , Scott M. Ebert, Christopher M. Adams
George R. Marcotte, … , Scott M. Ebert, Christopher M. Adams
Published October 10, 2023
Citation Information: JCI Insight. 2023;8(22):e171772. https://doi.org/10.1172/jci.insight.171772.
View: Text | PDF
Research Article Metabolism Muscle biology

GADD45A is a mediator of mitochondrial loss, atrophy, and weakness in skeletal muscle

  • Text
  • PDF
Abstract

Aging and many illnesses and injuries impair skeletal muscle mass and function, but the molecular mechanisms are not well understood. To better understand the mechanisms, we generated and studied transgenic mice with skeletal muscle–specific expression of growth arrest and DNA damage inducible α (GADD45A), a signaling protein whose expression in skeletal muscle rises during aging and a wide range of illnesses and injuries. We found that GADD45A induced several cellular changes that are characteristic of skeletal muscle atrophy, including a reduction in skeletal muscle mitochondria and oxidative capacity, selective atrophy of glycolytic muscle fibers, and paradoxical expression of oxidative myosin heavy chains despite mitochondrial loss. These cellular changes were at least partly mediated by MAP kinase kinase kinase 4, a protein kinase that is directly activated by GADD45A. By inducing these changes, GADD45A decreased the mass of muscles that are enriched in glycolytic fibers, and it impaired strength, specific force, and endurance exercise capacity. Furthermore, as predicted by data from mouse models, we found that GADD45A expression in skeletal muscle was associated with muscle weakness in humans. Collectively, these findings identify GADD45A as a mediator of mitochondrial loss, atrophy, and weakness in mouse skeletal muscle and a potential target for muscle weakness in humans.

Authors

George R. Marcotte, Matthew J. Miller, Hawley E. Kunz, Zachary C. Ryan, Matthew D. Strub, Patrick M. Vanderboom, Carrie J. Heppelmann, Sarah Chau, Zachary D. Von Ruff, Sean P. Kilroe, Andrew T. McKeen, Jason M. Dierdorff, Jennifer I. Stern, Karl A. Nath, Chad E. Grueter, Vitor A. Lira, Andrew R. Judge, Blake B. Rasmussen, K. Sreekumaran Nair, Ian R. Lanza, Scott M. Ebert, Christopher M. Adams

×

Figure 1

Transgenic mice with constitutive expression of GADD45A in skeletal muscle.

Options: View larger image (or click on image) Download as PowerPoint
Transgenic mice with constitutive expression of GADD45A in skeletal musc...
(A) Schematic illustration of skeletal muscle–specific GADD45A-transgenic mice (GADD45A-mTg mice), which express a mouse Gadd45a cDNA under control of the skeletal muscle–specific (human ACTA1 [HSA]) promoter. In GADD45A-mTg mice, a skeletal muscle–specific Cre recombinase transgene (HSA-MerCreMer) excises a Lox-STOP-Lox cassette upstream of the Gadd45a cDNA. In our studies of GADD45A-mTg mice, the control mice were littermates who lacked the HSA-MerCreMer transgene and thus retained the Lox-STOP-Lox cassette. (B) Heart, kidney, liver, soleus, triceps brachii (Triceps), and quadriceps femoris (Quad.) were collected from 15-month-old male littermate control and GADD45A-mTg mice, then subjected to quantitative PCR (qPCR) analysis of Gadd45a mRNA. Each circle represents the value from 1 animal, and bars indicate mean values. (C) Protein from quadriceps muscles of 15-month-old male littermate control (Ctrl) and GADD45A-mTg mice was subjected to tandem mass tag (TMT) labeling and mass spectrometry, followed by quantification of the relative abundance of GADD45A protein. Each circle represents the value from 1 animal, and bars indicate mean values. (D) Quadriceps and kidneys were harvested from littermate control and GADD45A-mTg mice at 2, 4, 6, and 8 weeks of age, then subjected to qPCR analysis of Gadd45a mRNA. Data are means ± SD from 2–3 control mice and 3–4 GADD45A-mTg mice per time point. Some error bars are too small to see. (E) Fractional abundance and rank order of all detected proteins, including GADD45A, in quadriceps muscle of 15-month-old male littermate control and GADD45A-mTg mice, as assessed by TMT-mass spectrometry.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts